Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
P. Tausche (Erlangen, Germany), D. Trufa (Erlangen, Germany), C. Geppert (Erlangen, Germany), R. Rieker (Erlangen, Germany), H. Sirbu (Erlangen, Germany), S. Neurath-Finotto (Erlangen, Germany). Late Breaking Abstract - Role of phosphorylated Signal Transducer and Activator of Transcription 5 (pSTAT5) in non-small cell lung cancer (NSCLC). 1643

Member's Comments

No comment yet.

Related content which might interest you: The Role of Signal Transducer and Activator of Transcription protein 1 (STAT1) in a murine model of lung adenocarcinoma (ADC) Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells Year: 2017 Role of hypoxia in epithelial-to-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 LSC - 2017 - Proteasomal Activator 200 (PA200) Regulates Cellular Proliferation: A Putative Role For IPF And Lung Cancer Pathogenesis Source: International Congress 2017 – New insights into pathogenesis of lung disease  Year: 2017 Expression of the ILK-PINCH-PARVIN (IPP) complex and its binding partner Rsu-1 in human non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 Late Breaking Abstract - Induction of the transcriptional repressor B lymphocytes-induced maturation protein-1 (Blimp-1) in lung cancer Source: Virtual Congress 2020 – Biological aspects of lung cancer Year: 2020 Hypoxia Promotes Human NSCLC Cell Line A549 Motility and EMT Through Extracellular HSP90a Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells Year: 2017 Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Tumor-associated stromal gene expression signatures predict therapeutic response to erlotinib/bevacizumab in non-small cell lung cancer (NSCLC) Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Late Breaking Abstract - Anaplastic Lymphoma Kinase inhibition as an effective treatment strategy against the enhanced lung carcinogenesis and cancer angiogenesis related to decreased PTPRZ1 expression Source: Virtual Congress 2020 – Biological aspects of lung cancer Year: 2020 XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 A role for cAMP-responsive element binding protein in lung adenocarcinoma Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours Year: 2015 Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours Year: 2015 LATE-BREAKING ABSTRACT: Early relapse of non-small cell lung cancer (NSCLC) found after CNS-symptoms Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Translocation of beta-catenin into cytoplasm during TGFbeta-induced EMT is negatively regulated by phosphorylation of the PTEN C-terminus in lung cancers Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases Year: 2013 Nuclear expression of Y-Box binding protein (YB-1) as a negative prognostic marker in non-small cell lung cancer Source: Annual Congress 2003 - Lung cancer biology Year: 2003 The impact of ß-blockers in non–small cell lung cancer patients treated with Epidermal Growth Factor Receptor Kinase Inhibitors, Taiwan NHIRD database study. Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018 Clinical significance of erythropoietin (Epo) and its receptor (EpoR) in non-small cell lung carcinoma Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level? Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Treatment of  non-small cell lung cancer (NSCLC) - the state of the art and beyond Source: International Congress 2017 – State of the art session: "Lung cancer" Year: 2017